A Phase 3 Randomized Open-label Study of Pasritamig (JNJ-78278343) a T-cell-redirecting Agent Targeting Human Kallikrein 2 With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

Brief description of study

A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer


Clinical Study Identifier: s25-01742
ClinicalTrials.gov Identifier: NCT07225946
Principal Investigator: David R. Wise.
Other Investigators: Mary K O'Keeffe, Andrew Laccetti, Victor Ricardo Adorno Febles, Kenia J Rodriguez, Tiffany M Tomberlin, Laura Catherine Bauer, Doris M Salazar, Minas Platon Economides.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.